Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
unmodified EBV-specific T cells
- Development stage
- Unknown
- Lead developer
- Baylor College of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Unmodified EBV-specific T cells (EBVSTs) are a form of adoptive cellular immunotherapy consisting of autologous or allogeneic T lymphocytes that have been expanded ex vivo to specifically recognize and eliminate cells expressing Epstein-Barr virus (EBV) antigens. Unlike genetically engineered products such as CAR-T cells, these EBVSTs utilize their endogenous T-cell receptors (TCRs) to identify viral peptides presented by HLA molecules on the surface of infected or malignant cells. Developed primarily by investigators at Baylor College of Medicine and St. Jude Children's Research Hospital, EBVSTs are utilized to treat EBV-associated malignancies, including Hodgkin lymphoma, B-cell non-Hodgkin lymphoma, and nasopharyngeal carcinoma. In clinical research, they have demonstrated a favorable safety profile and are frequently employed as a benchmark control group to evaluate the long-term risks, such as genotoxicity and secondary malignancies, associated with modified cellular therapies.
- Other names
- Epstein-Barr virus-specific T lymphocytesEBV-VSTsEBV-CTLsEpstein-Barr virus-specific T cells
02
Targets
BARF1 (Epstein-Barr virus BARF1 protein)pMHC (Peptide-MHC complex family)Epstein-Barr virus latent membrane protein 1-derived peptide–Major Histocompatibility ComplexEpstein-Barr virus latent membrane protein 2-derived peptide–major histocompatibility complex (EBV LMP2-pMHC)
Beyond the preview
Go deeper on unmodified EBV-specific T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on unmodified EBV-specific T cells.